Effects of Aloe vera Supplementation in Subjects with Prediabetes/Metabolic Syndrome
Publication: Metabolic Syndrome and Related Disorders
Volume 11, Issue Number 1
Abstract
Background: Metabolic syndrome affects 1 in 3 U.S. adults. The primary target of treatment of patients with metabolic syndrome is therapeutic lifestyle change. Numerous animal trials have reported positive effects of Aloe vera in in vivo models of diabetes, but there is a paucity of controlled clinical trials in patients with prediabetes. Thus, the objective of this pilot study was to examine the effect of aloe compared to placebo on fasting blood glucose, lipid profile, and oxidative stress in subjects with prediabetes/metabolic syndrome.
Methods: This was a double-blind, placebo-controlled Institutional Review Board (IRB)–approved pilot study of two aloe products (UP780 and AC952) in patients with prediabetes over an 8-week period. A total of 45 subjects with impaired fasting glucose or impaired glucose tolerance and having two other features of metabolic syndrome were recruited (n=15/group). Parameters of glycemia [fasting glucose, insulin, homeostasis model assessment (HOMA), glycosylated hemoglobin (HbA1c), fructosamine, and oral glucose tolerance test (OGTT)] and oxidative stress (urinary F2-isoprostanes) were measured along with lipid profile and high-sensitivity C-reactive protein (hsCRP) levels before and after supplementation.
Results: There were no significant baseline differences between groups. Compared to placebo, only the AC952 Aloe vera inner leaf gel powder resulted in significant reduction in total and low-density lipoprotein cholesterol (LDL-C) levels, glucose, and fructosamine. In the UP780 Aloe vera inner leaf gel powder standardized with 2% aloesin group, there were significant reductions in HbA1c, fructosamine, fasting glucose, insulin, and HOMA. Only the UP780 aloe group had a significant reduction in the F2-isoprostanes compared to placebo.
Conclusions: Standardized aloe preparations offer an attractive adjunctive strategy to revert the impaired fasting glucose and impaired glucose tolerance observed in conditions of prediabetes/metabolic syndrome.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular riskJ AmColl Cardiol201259635-643. 1. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J AmColl Cardiol 2012;59:635–643.
2.
Alberti KGEckel RHGrundy SM et al.International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of ObesityCirculation20091201640-1645. 2. Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645.
3.
Grundy SMCleeman JIDaniels SR et al.American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific StatementCirculation20051122735-2752. 3. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752.
4.
Ajabnoor MA. Effect of aloes on blood glucose levels in normal and alloxan diabetic miceJ Ethnopharmacol199028215-220. 4. Ajabnoor MA. Effect of aloes on blood glucose levels in normal and alloxan diabetic mice. J Ethnopharmacol 1990;28:215–220.
5.
Ghannam NKingston MAl-Meshaal IA et al. The antidiabetic activity of aloes: Preliminary clinical and experimental observationsHorm Res198624288-294. 5. Ghannam N, Kingston M, Al-Meshaal IA, et al. The antidiabetic activity of aloes: Preliminary clinical and experimental observations. Horm Res 1986;24:288–294.
6.
Rajasekaran SSivagnanam KRavi K et al. Hypoglycemic effect of Aloe vera gel on streptozotocin-induced diabetes in experimental ratsJ Med Food2004761-66. 6. Rajasekaran S, Sivagnanam K, Ravi K, et al. Hypoglycemic effect of Aloe vera gel on streptozotocin-induced diabetes in experimental rats. J Med Food 2004;7:61–66.
7.
al-Awadi FFatania HShamte U. The effect of a plants mixture extract on liver gluconeogenesis in streptozotocin induced diabetic ratsDiabetes Res199118163-168. 7. al-Awadi F, Fatania H, Shamte U. The effect of a plants mixture extract on liver gluconeogenesis in streptozotocin induced diabetic rats. Diabetes Res 1991;18:163–168.
8.
Parihar MSChaudhary MShetty R et al. Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: Prevention by extracts of Withania somnifera and Aloe veraJ Clin Neurosci200411397-402. 8. Parihar MS, Chaudhary M, Shetty R, et al. Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: Prevention by extracts of Withania somnifera and Aloe vera. J Clin Neurosci 2004;11:397–402.
9.
Bolkent SAkev NOzsoy N et al. Effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on kidney in type-II diabetic rat modelsIndian J Exp Biol20044248-52. 9. Bolkent S, Akev N, Ozsoy N, et al. Effect of Aloe vera (L.) Burm. fil. leaf gel and pulp extracts on kidney in type-II diabetic rat models. Indian J Exp Biol 2004;42:48–52.
10.
Can AAkev NOzsoy N et al. Effect of Aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat modelsBiol Pharm Bull200427694-698. 10. Can A, Akev N, Ozsoy N, et al. Effect of Aloe vera leaf gel and pulp extracts on the liver in type-II diabetic rat models. Biol Pharm Bull 2004;27:694–698.
11.
Rajasekaran SRavi KSivagnanam K et al. Beneficial effects of aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetesClin Exp Pharmacol Physiol200633232-237. 11. Rajasekaran S, Ravi K, Sivagnanam K, et al. Beneficial effects of aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes. Clin Exp Pharmacol Physiol 2006;33:232–237.
12.
Yongchaiyudha SRungpitarangsi VBunyapraphatsara N et al. Antidiabetic activity of Aloe vera L juice. I. Clinical trial in new cases of diabetes mellitusPhytomedicine19963241-243. 12. Yongchaiyudha S, Rungpitarangsi V, Bunyapraphatsara N, et al. Antidiabetic activity of Aloe vera L juice. I. Clinical trial in new cases of diabetes mellitus. Phytomedicine 1996;3:241–243.
13.
Bunyapraphatsara NYongchaiyudha SRungpitarangsi V et al. Antidiabetic activity of Aloe vera L juice.I. Clinical trial in diabetes mellitus patients in combination with glibenclamidePhytomedicine19963245-248. 13. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, et al. Antidiabetic activity of Aloe vera L juice.I. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomedicine 1996;3:245–248.
14.
Huseini HFKianbakht SHajiaghaee R et al. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trialPlanta Med201278311-316. 14. Huseini HF, Kianbakht S, Hajiaghaee R, et al. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: A randomized double-blind placebo-controlled clinical trial. Planta Med 2012;78:311–316.
15.
Devaraj SHirany SVBurk RF et al. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetesClin Chem.2001471974-1979. 15. Devaraj S, Hirany SV, Burk RF, et al. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem. 2001;47:1974–1979.
16.
Vega-López SDevaraj SJialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular diseaseJ Investig Med2004224-32. 16. Vega-López S, Devaraj S, Jialal I. Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med 2004;2:24–32.
17.
Tsai IJCroft KDMori TA et al. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reductionFree Radic Biol Med200946263-270. 17. Tsai IJ, Croft KD, Mori TA, et al. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. Free Radic Biol Med 2009;46:263–270.
18.
Rajasekaran SSivagnanam KSubramanian S. Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in ratsPharmacol Rep20055790-96. 18. Rajasekaran S, Sivagnanam K, Subramanian S. Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats. Pharmacol Rep 2005;57:90–96.
Information & Authors
Information
Published In

Metabolic Syndrome and Related Disorders
Volume 11 • Issue Number 1 • February 2013
Pages: 35 - 40
PubMed: 23035844
Copyright
Copyright 2013, Mary Ann Liebert, Inc.
History
Published in print: February 2013
Published online: 23 January 2013
Published ahead of print: 4 October 2012
Authors
Author Disclosure Statement
S.D received a grant from Unigen and MY, LAB, QJ are employed at Unigen.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.